The results showed that IPI score, treatment modalities, Hans classification, administration of rituximab, and Ki-67 and Myc/Bcl-2 protein co-expression were significantly associated with prognosis (P < 0.05), while patient age, sex, tumor size, B symptoms, Hashimoto's thyroiditis existence, BCL-2 expression level, MYC expression level, serum LDH level, and tumor stage were not significantly associated with prognosis (P > 0.05; Table 1). The gene discussed is BCL2; the disease is neoplasm.